Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

xisomab 3G3

A humanized anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, xisomab 3G3 targets and binds to the apple 2 domain of FXI, thereby preventing the binding of FXI to factor XIIa (FXIIa). This blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT), and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-factor XI monoclonal antibody xisomab 3G3
anti-FXI antibody xisomab 3G3
Code name:AB 023
AB-023
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search